Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Canada Biosimilars Proposal Requires Extra Studies To Show Substitutability

Executive Summary

Substitution of a biosimilar for its reference brand product would not be automatic under the framework proposed by Health Canada for approving what it calls "subsequent entry biologics.

You may also be interested in...

Potential Federal Drug Savings Could Propel Biosimilars Bill

The potential for biosimilars to lower Medicare and Medicaid drug spending could help catalyze support for a follow-on biologics bill this year, a Capitol Hill staffer predicted at the Food and Drug Law Institute's annual conference March 26

Amgen’s European EPO Sales Unaffected By Biosimilars, Company Says

The European launch of biosimilar erythropoietin products has failed to impact European sales of Amgen's EPO products, EVP Worldwide Sales and Marketing George Morrow said during the company's third quarter earnings call Oct. 24

European Biosimilar Guidelines May Leave Room For Regulatory Shortcuts

Marketing authorization for generic biologics may be extrapolated to additional indications approved for the reference product, according to biosimilar guidelines recently released by the European Medicines Agency

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts